Anal canal adenocarcinoma due to human papillomavirus: unusual report of a case

Camila Bras Harriott; Maximiliano E. Bun; Nicolas A. Rotholtz

doi:10.18203/issn.2454-2156.IntJSciRep20260037

Authors

Camila Bras Harriott Department of General Surgery, Colorectal Unit, Hospital Alemán of Buenos Aires, Argentina
Maximiliano E. Bun Department of General Surgery, Colorectal Unit, Hospital Alemán of Buenos Aires, Argentina
Nicolas A. Rotholtz Department of General Surgery, Colorectal Unit, Hospital Alemán of Buenos Aires, Argentina

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20260037

Keywords:

Anal canal adenocarcinoma, Human papillomavirus, Transicional adenocarcinoma, Anal canal cancer

Abstract

Anal adenocarcinoma (AC) is a rare malignancy, accounting for only 5% of anal cancers, and presents significant diagnostic and therapeutic challenges due to its low incidence and limited data. The most common type of anal cancer is squamous cell carcinoma (SCC), commonly associated with human papillomavirus (HPV) infection. However, AC, particularly transitional type, has distinct clinical and biological profile. This case report discusses 66-year-old female with anal canal transitional adenocarcinoma associated with HPV, presenting with 2 cm tumor at anal verge. Diagnosis was confirmed through biopsy and imaging studies revealed no lymph node involvement. Patient underwent successful transanal resection with clear margins and post-op recovery was uneventful. Follow-up included regular clinical and imaging evaluations, with no signs of recurrence after 2 years. Treatment options for anal AC include local resection for small, well-differentiated tumors, and chemoradiotherapy for select cases. Prognostic factors such as age, tumor size and nodal involvement significantly influence survival outcomes. Continued research and case studies are necessary to refine treatment approaches and improve long-term patient care for AC.

Metrics

Metrics Loading ...

References

English KJ. Anal carcinoma-exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment. World J Exp Med. 2024;14(3):98525. DOI: https://doi.org/10.5493/wjem.v14.i3.98525

Katerji R, Liao X, Huber A, Zhang D. An Unusual Case of Human Papillomavirus-Related Anorectal Adenocarcinoma With Progression to Perianal Paget's Disease. Int J Surg Pathol. 2021;29(6):672-6. DOI: https://doi.org/10.1177/1066896920982367

Voltaggio L, McCluggage WG, Iding JS, Martin B, Longacre TA, Ronnett BM. A novel group of HPV-related adenocarcinomas of the lower anogenital tract (vagina, vulva, and anorectum) in women and men resembling HPV-related endocervical adenocarcinomas. Mod Pathol. 2020;33(5):944-52. DOI: https://doi.org/10.1038/s41379-019-0437-z

Belkacémi Y, Rouanet P, Jafari M. Primary adenocarcinoma of the anal canal. In: Belkacémi Y, Mirimanoff RO, Ozsahin M. (eds) Management of Rare Adult Tumours. Springer, Paris. 2009. DOI: https://doi.org/10.1007/978-2-287-92246-6

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. Version 1. 2025.

Meriden Z, Montgomery EA. Anal duct carcinoma: a report of 5 cases. Hum Pathol. 2012;43(2):216-20. DOI: https://doi.org/10.1016/j.humpath.2011.04.019

Tsay CJ, Pointer T, Chandler JB, Nagar AB, Protiva P. Anal adenocarcinoma: case report, literature review and comparative survival analysis. BMJ Open Gastroenterol. 2021;8(1):e000661. DOI: https://doi.org/10.1136/bmjgast-2021-000661

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1. 2025. Available at: nccn.org. Accessed on 15 November 2025.

Ferrer Márquez M, Velasco Albendea FJ, Belda Lozano R, Berenguel Ibáñez Mdel M, Reina Duarte Á. Adenocarcinoma of the anal canal. Narrative review. Cir Esp. 2013;91(5):281-6. DOI: https://doi.org/10.1016/j.cireng.2013.10.017

Taliadoros V, Rafique H, Rasheed S, Tekkis P, Kontovounisios C. Management and Outcomes in Anal Canal Adenocarcinomas-A Systematic Review. Cancers (Basel). 2022;14(15):3738. DOI: https://doi.org/10.3390/cancers14153738

Herfs M, Roncarati P, Koopmansch B. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. Br J Cancer. 2018;118(10):1302-12. DOI: https://doi.org/10.1038/s41416-018-0049-2

Lukovic J, Kim JJ, Krzyzanowska M, Chadi SA, Taniguchi CM, Hosni A. Anal Adenocarcinoma: A Rare Malignancy in Need of Multidisciplinary Management. JCO Oncol Pract. 2020;16(10):635-40. DOI: https://doi.org/10.1200/OP.20.00363